LINCOLNSHIRE – Eli Lilly and Company (NYSE: LLY) and Nexus Pharmaceuticals, LLC today announced a definitive agreement for Lilly to acquire a manufacturing facility from Nexus, a leading sterile manufacturer in the pharmaceutical industry. The acquisition of this FDA-approved facility in Pleasant Prairie, Wisconsin will further expand Lilly’s global parenteral (injectable) product manufacturing network and support increased demand for the …